Literature DB >> 27893188

DEK oncogene is overexpressed during melanoma progression.

Erica Riveiro-Falkenbach1, Yolanda Ruano1, Rosa M García-Martín1, David Lora2, Metehan Cifdaloz3, Francesco Acquadro4, Claudio Ballestín1, Pablo L Ortiz-Romero5, María S Soengas3, José L Rodríguez-Peralto1.   

Abstract

DEK is an oncoprotein involved in a variety of cellular functions, such as DNA repair, replication, and transcriptional control. DEK is preferentially expressed in actively proliferating and malignant cells, including melanoma cell lines in which DEK was previously demonstrated to play a critical role in proliferation and chemoresistance. Still, the impact of this protein in melanoma progression remains unclear. Thus, we performed a comprehensive analysis of DEK expression in different melanocytic tumors. The immunostaining results of 303 tumors demonstrated negligible DEK expression in benign lesions. Conversely, malignant lesions, particularly in metastatic cases, were largely positive for DEK expression, which was partially associated with genomic amplification. Importantly, DEK overexpression was correlated with histological features of aggressiveness in primary tumors and poor prognosis in melanoma patients. In conclusion, our study provides new insight into the involvement of DEK in melanoma progression, as well as proof of concept for its potential application as a marker and therapeutic target of melanoma.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990DEKzzm321990; melanoma; oncogene; overexpression; progression

Mesh:

Substances:

Year:  2017        PMID: 27893188     DOI: 10.1111/pcmr.12563

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  15 in total

1.  The nuclear DEK interactome supports multi-functionality.

Authors:  Eric A Smith; Eric F Krumpelbeck; Anil G Jegga; Malte Prell; Marie M Matrka; Ferdinand Kappes; Kenneth D Greis; Abdullah M Ali; Amom R Meetei; Susanne I Wells
Journal:  Proteins       Date:  2017-11-11

2.  NU-6027 Inhibits Growth of Mycobacterium tuberculosis by Targeting Protein Kinase D and Protein Kinase G.

Authors:  Sohini Chakraborti; Neha Khare; Sumana Das; Saqib Kidwai; Rania Bouzeyen; Tannu Priya Gosain; Assirbad Behura; Chhuttan Lal Meena; Rohan Dhiman; Makram Essafi; Avinash Bajaj; Deepak Kumar Saini; Narayanaswamy Srinivasan; Dinesh Mahajan; Ramandeep Singh
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

Review 3.  A role for intracellular and extracellular DEK in regulating hematopoiesis.

Authors:  Maegan L Capitano; Hal E Broxmeyer
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

4.  MiR-138-5p Inhibits the Proliferation of Gastric Cancer Cells by Targeting DEK.

Authors:  Wei Zhang; Kai Liao; Dongning Liu
Journal:  Cancer Manag Res       Date:  2020-09-08       Impact factor: 3.989

5.  Prognostic role of DEK in human solid tumors: a meta-analysis.

Authors:  Gang Liu; Disheng Xiong; Junjie Zeng; Guoxing Xu; Rui Xiao; Borong Chen; Zhengjie Huang
Journal:  Oncotarget       Date:  2017-07-29

6.  Dek overexpression in murine epithelia increases overt esophageal squamous cell carcinoma incidence.

Authors:  Marie C Matrka; Katherine A Cimperman; Sarah R Haas; Geraldine Guasch; Lisa A Ehrman; Ronald R Waclaw; Kakajan Komurov; Adam Lane; Kathryn A Wikenheiser-Brokamp; Susanne I Wells
Journal:  PLoS Genet       Date:  2018-03-14       Impact factor: 5.917

7.  The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.

Authors:  Magdalena Ganz; Christopher Vogel; Christina Czada; Vera Jörke; Eva Christina Gwosch; Rebecca Kleiner; Agnieszka Pierzynska-Mach; Francesca Cella Zanacchi; Alberto Diaspro; Ferdinand Kappes; Alexander Bürkle; Elisa Ferrando-May
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

8.  A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Authors:  Masanori Oshi; Fernando A Angarita; Yoshihisa Tokumaru; Li Yan; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Journal:  Cancers (Basel)       Date:  2021-05-16       Impact factor: 6.639

9.  Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1.

Authors:  Metehan Cifdaloz; Lisa Osterloh; Osvaldo Graña; Erica Riveiro-Falkenbach; Pilar Ximénez-Embún; Javier Muñoz; Cristina Tejedo; Tonantzin G Calvo; Panagiotis Karras; David Olmeda; Belén Miñana; Gonzalo Gómez-López; Estela Cañon; Eduardo Eyras; Haihong Guo; Ferdinand Kappes; Pablo L Ortiz-Romero; Jose L Rodríguez-Peralto; Diego Megías; Juan Valcárcel; María S Soengas
Journal:  Nat Commun       Date:  2017-12-21       Impact factor: 14.919

Review 10.  NUP214 in Leukemia: It's More than Transport.

Authors:  Adélia Mendes; Birthe Fahrenkrog
Journal:  Cells       Date:  2019-01-21       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.